>>> Boston Scientific reports EPS in-line, revs in-line; guides Q2 EPS in-line,

Boston Scientific reports EPS in-line, revs in-line; guides Q2 EPS in-line, revs below consensus; reaffirms FY15 EPS guidance, guides FY15 revs below consensus

Reports Q1 (Mar) earnings of $0.21 per share, in-line with the Capital IQ Consensus Estimate of $0.21; revenues fell 0.2% year/year to $1.77 bln vs the $1.78 bln consensus.

Co issues mixed guidance for Q2, sees EPS of $0.20-0.22 vs. $0.22 Capital IQ Consensus Estimate; sees Q2 revs of $1.800-1.850 vs. $1.86 bln Capital IQ Consensus Estimate.
Co issues mixed guidance for FY15, sees EPS of $0.878-0.92 vs. $0.91 Capital IQ Consensus Estimate; sees FY15 revs of $7.225-7.375 vs. $7.46 bln Capital IQ Consensus Estimate.
"We achieved strong results in the first quarter, and we continue to build global momentum." said Mike Mahoney, president and chief executive officer, Boston Scientific. "In particular, our Interventional Cardiology business, including structural heart, delivered excellent results. We are also excited about bringing new innovation to patients with the recent Food and Drug Administration approvals of the WATCHMAN™ Left Atrial Appendage Closure Device and the EMBLEM™ Subcutaneous Implantable Defibrillator System."